Korean guidelines for the management of gout

키워드

참고문헌 (38)

1. Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
2. Kim SY, "Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity", J Clin Epidemiol, 66, pp.408~414 (2013)
3. Schünemann H, "GRADE handbook" (2013), GRADE Working Group
4. Andrews J, "GRADE guidelines : 14. Going from evidence to recommendations : the significance and presentation of recommendations", J Clin Epidemiol, 66, pp.719~725 (2013)
5. Chung Min Kyung, "Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence", Journal of Korean Medical Science, 36(32), pp.1~9 (2021), 대한의학회[DOI]
6. Alloway JA, "Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis", J Rheumatol, 20, pp.111~113 (1993)
7. Billy CA, "Corticosteroid or nonsteroidal antiinflammatory drugs for the treatment of acute gout : a systematic review of randomized controlled trials", J Rheumatol, 45, pp.128~136 (2018)
8. Roddy E, "Open-label randomised pragmatic trial(CONTACT)comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care", Ann Rheum Dis, 79, pp.276~284 (2020)
9. Eminaga F, "Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks:a systematic literature review", Rheumatol Int, 36, pp.1747~1752 (2016)
10. Feng X, "Significance of the initiation time of urate-lowering therapy in gout patients : a retrospective research", Joint Bone Spine, 82, pp.428~431 (2015)
11. Hill EM, "Does starting allopurinol prolong acute treated gout? A randomized clinical trial", J Clin Rheumatol, 21, pp.120~125 (2015)
12. Sun R, "Evaluation of febuxostat initiation during an acute gout attack : a prospective, randomized clinical trial", Joint Bone Spine, 87, pp.461~466 (2020)
13. Taylor TH, "Initiation of allopurinol at first medical contact for acute attacks of gout : a randomized clinical trial", Am J Med, 125, pp.1126~1134 (2012)
14. Borstad GC, "Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis", J Rheumatol, 31, pp.2429~2432 (2004)
15. Mitha E, "Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial", Rheumatology(Oxford), 52, pp.1285~1292 (2013)
16. Paulus HE, "Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients", Arthritis Rheum, 17, pp.609~614 (1974)
17. Poiley J, "A randomized, double-blind, active-and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout", Arthritis Rheumatol, 68, pp.2027~2034 (2016)
18. Schlesinger N, "Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment : results of a double-blind, randomised study", Ann Rheum Dis, 70, pp.1264~1271 (2011)
19. Schumacher HR Jr, "Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study", Arthritis Care Res(Hoboken), 64, pp.1462~1470 (2012)
20. Schumacher HR Jr, "Rilonacept(interleukin-1 trap)in the prevention of acute gout flares during initiation of urate-lowering therapy : results of a phase II randomized, double-blind, placebo-controlled trial", Arthritis Rheum, 64, pp.876~884 (2012)
21. Sundy JS, "Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy : results of RESURGE, a phase III, international safety study", J Rheumatol, 41, pp.1703~1711 (2014)
22. Yamanaka H, "Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy : results from FORTUNE-1, a prospective, multicentre randomised study", Ann Rheum Dis, 77, pp.270~276 (2018)
23. Solomon DH, "Effects of colchicine on risk of cardiovascular events and mortality among patients with gout : a cohort study using electronic medical records linked with Medicare claims", Ann Rheum Dis, 75, pp.1674~1679 (2016)
24. Yu J, "Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting", Mod Rheumatol, 28, pp.339~344 (2018)
25. Shiozawa A, "Serum uric acid and the risk of incident and recurrent gout : a systematic review", J Rheumatol, 44, pp.388~396 (2017)
26. 주고운, "Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy", Journal of Korean Medical Science, 29(5), pp.657~661 (2014), 대한의학회
27. Latourte A, "Dyslipidemia, alcohol consumption, and obesity as main factors associated with poor control of urate levels in patients receiving urate-lowering therapy", Arthritis Care Res(Hoboken), 70, pp.918~924 (2018)
28. Dalbeth N, "Effects of allopurinol dose escalation on bone erosion and urate volume in gout : a dual-energy computed tomography imaging study within a randomized, controlled trial", Arthritis Rheumatol, 71, pp.1739~1746 (2019)
29. Araujo EG, "Tophus resolution with pegloticase : a prospective dual-energy CT study", RMD Open, 1, pp.e000075~ (2015)
30. Villaverde V, "Systematic review of the value of ultrasound and magnetic resonance musculoskeletal imaging in the evaluation of response to treatment of gout", Reumatol Clin, 10, pp.160~163 (2014)
31. Hui M, "The British Society for Rheumatology guideline for the management of gout", Rheumatology (Oxford), 56, pp.e1~e20 (2017)
32. Richette P, "2016 updated EULAR evidence-based recommendations for the management of gout", Ann Rheum Dis, 76, pp.29~42 (2017)
33. Beslon V, "Effects of discontinuation of urate-lowering therapy : a systematic review", J Gen Intern Med, 33, pp.358~366 (2018)
34. Perez-Ruiz F, "Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout", Arthritis Rheum, 47, pp.356~360 (2002)
35. Borghi C, "Serum uric acid and the risk of cardiovascular and renal disease", J Hypertens, 33, pp.1729~1741 (2015)
36. Suliman ME, "J-shaped mortality relationship for uric acid in CKD", Am J Kidney Dis, 48, pp.761~771 (2006)
37. Wang H, "Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function : a meta-analysis", J Ren Nutr, 23, pp.389~396 (2013)
38. 김솔잎, "Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis", Kidney Research and Clinical Practice, 36(3), pp.274~281 (2017), 대한신장학회

관련 논문AI추천